Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Sera Prognostics to Present at the 11th Annual Canaccord Genuity Medical Technologies and Diagnostics Forum


Posted on: 06 Nov 17

SALT LAKE CITY, Nov. 06, 2017 (GLOBE NEWSWIRE) -- Sera Prognostics, Inc., a women’s healthcare company, today announced that Gregory C. Critchfield, M.D., M.S., Chairman and Chief Executive Officer, will present at the upcoming Canaccord Genuity Medical Technologies and Diagnostics Forum in New York City. Dr. Critchfield’s presentation will take place at 2:30 PM E.T. on Thursday, November 9th, at the Westin Grand Central Hotel.

Sera Prognostics management will be available for one-on-one meetings with conference attendees after the presentation.

About the PreTRM® Test

The PreTRM® test is the first and only broadly clinically-validated blood test that provides an early and individual risk prediction for spontaneous preterm birth in asymptomatic, singleton pregnancies. The PreTRM test measures and analyzes proteins in the blood that are highly predictive of preterm birth.  The PreTRM test can help physicians identify early in the pregnancy (as early as 19 weeks of gestation) which women are at increased risk for premature delivery, enabling more informed clinical decisions based on each woman’s individual risk. The PreTRM test enables researchers to better understand the causes of preterm birth and to develop new therapies to improve newborn health.

The PreTRM test is ordered by a medical professional.

For more information about the PreTRM test, please visit www.PreTRM.com and the PreTRM test YouTube Channel.  You can also join the conversation on Facebook and @PreTRM.

About Sera Prognostics, Inc.

Sera Prognostics is a global leader in high value women’s health diagnostics, delivering pivotal information to physicians to improve health and improve the economics of healthcare delivery for pregnant women.  Sera is developing innovative diagnostic tests focused on the early prediction of preterm birth (PTB) risk and other complications of pregnancy. The Company recently launched its first product, the PreTRM® test, nationwide through LabCorp’s expansive 1750 network of patient service centers.  PreTRM is the first and only broadly clinically-validated blood test to accurately predict early in pregnancy the risk of premature birth. The test objectively reports to the physician the risk of premature delivery, enabling earlier proactive interventions designed to prolong gestation and improve neonatal health outcomes. Sera’s strong management team has significant clinical development and women's healthcare diagnostic experience. Sera is backed by highly respected healthcare investors, including Domain Associates, InterWest Partners, Catalyst Health Ventures, the Bill & Melinda Gates Foundation, and LabCorp, the exclusive U.S. distributor of the PreTRM test. Currently, Sera is working with the Gates Foundation to translate the Company’s discoveries into technologies well suited for low-income countries in its journey to improve maternal and infant health globally. Sera Prognostics is located in Salt Lake City, Utah. For more information, please visit the company's website at  www.seraprognostics.com

Company Contact:
Andrew Sauter
Sera Prognostics
asauter@seraprognostics.com  
(801) 990-0772

Communications Contact:
Terri Clevenger
Continuum Health Communications
tclevenger@continuumhealthcom.com 
(203)856-4326

GlobeNewswire
globenewswire.com

Last updated on: 07/11/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.